Match!
Mehdi Najafzadeh
Brigham and Women's Hospital
Intensive care medicinePhysical therapyEmpagliflozinQuality-adjusted life yearMedicine
79Publications
18H-index
1,739Citations
What is this?
Publications 80
Newest
#1Jonathan J. Darrow (Brigham and Women's Hospital)H-Index: 11
#2Mehdi Najafzadeh (Brigham and Women's Hospital)H-Index: 18
Last. Aaron S. Kesselheim (Brigham and Women's Hospital)H-Index: 44
view all 4 authors...
Summary Antimicrobial resistance is of growing concern. To encourage development of new treatments, some commentators have suggested regulators exercise increased flexibility on the clinical evidence required for approval. We examined all 1065 new drugs and biologics approved by the US Food and Drug Administration between 1984 and 2018 and recorded each drug's use of the Orphan Drug Act, fast-track, priority review, accelerated approval, and breakthrough therapy programmes, as well as dates of i...
Source
#1Elisabetta PatornoH-Index: 22
#2Ajinkya PawarH-Index: 7
Last. Seabastian SchneeweissH-Index: 1
view all 9 authors...
Source
#1Elisabetta PatornoH-Index: 22
#2Ajinkya PawarH-Index: 7
Last. Seabastian SchneeweissH-Index: 1
view all 10 authors...
EMPRISE aims to study the effectiveness, safety and healthcare utilization of empagliflozin (EMPA) in routine care patients. In an interim analysis, we assessed the comparative cardiovascular (CV) effectiveness of EMPA in older adults. Using data from Medicare (2014-2017), we identified 11,579 pairs of 1:1 propensity score-matched patients ≥66 years with type 2 diabetes initiating EMPA or a DPP-4 inhibitor (DPP-4i), and 17,500 pairs initiating EMPA or a GLP-1 receptor agonist (GLP-1RA). We asses...
Source
#1Katie A. Greenzang (Harvard University)H-Index: 4
#2Hasan Al-Sayegh (Harvard University)H-Index: 9
Last. Jennifer W. Mack (Harvard University)H-Index: 32
view all 6 authors...
BACKGROUND: More than 80% of children with cancer become long-term survivors, yet most survivors experience late effects of treatment. Little is known about how parents and physicians consider late-effects risks against a potential survival benefit when making treatment decisions. METHODS: We used a discrete choice experiment to assess the importance of late effects on treatment decision-making and acceptable trade-offs between late-effects risks and survival benefit. We surveyed 95 parents of c...
2 CitationsSource
#1Macarius M. Donneyong (OSU: Ohio State University)H-Index: 9
#2Teng-Jen Chang (OSU: Ohio State University)
Last. JoAnn E. Manson (Brigham and Women's Hospital)H-Index: 240
view all 10 authors...
OBJECTIVES: The Women's Health Initiative (WHI) randomized trial identified age differences in the benefit-risk profile of estrogen-alone (ET) use. The impact of WHI trial on disease-associated medical expenditures attributable to subsequent decreased ET utilization has, however, not been measured. Therefore, the objective of this analysis was to quantify the age-specific disease-associated medical expenditures attributable to reduced ET utilization after the WHI Hormone Therapy (HT) trials. MET...
Source
Source
#1Ivair R. SilvaH-Index: 5
#2Joshua J. Gagne (Brigham and Women's Hospital)H-Index: 31
Last. Martin Kulldorff (Brigham and Women's Hospital)H-Index: 63
view all 4 authors...
Sequential analysis is used in clinical trials and postmarket drug safety surveillance to prospectively monitor efficacy and safety to quickly detect benefits and problems, while taking the multiple testing of repeated analyses into account. When there are multiple outcomes, each one may be given a weight corresponding to its severity. This paper introduces an exact sequential analysis procedure for multiple weighted binomial end points; the analysis incorporates a drug's combined benefit and sa...
Source
#1Jennifer Donnan (St. John's University)H-Index: 7
#2Karissa Johnston (St. John's University)
Last. John-Michael Gamble (St. John's University)H-Index: 15
view all 8 authors...
Abstract Objectives To estimate the strength of preferences, relative importance and trade-offs that patients with type 2 diabetes make between characteristics of antihyperglycemic medications. Methods We conducted a discrete choice experiment with a sample of Canadians with type 2 diabetes. Respondents completed 14 choice tasks and choose between 2 hypothetical drug alternatives, described by 8 characteristics (cost, efficacy, life expectancy, risk of macrovascular event, risk of microvascular ...
Source
#1Elvira D’Andrea (Brigham and Women's Hospital)H-Index: 10
#2Niteesh K. Choudhry (Brigham and Women's Hospital)H-Index: 54
Last. Mehdi Najafzadeh (Brigham and Women's Hospital)H-Index: 18
view all 5 authors...
: Bronchoscopy is the safest procedure for lung cancer diagnosis when an invasive evaluation is required after imaging procedures. However, its sensitivity is relatively low, especially for small and peripheral lesions. We assessed benefits and costs of introducing a bronchial gene-expression classifier (BGC) to improve the performance of bronchoscopy and the overall diagnostic process for early detection of lung cancer. We used discrete-event simulation to compare clinical and economic outcomes...
1 CitationsSource
#1Elisabetta Patorno (Brigham and Women's Hospital)H-Index: 22
#2Mehdi Najafzadeh (Brigham and Women's Hospital)H-Index: 18
Last. Seabastian Schneeweiss (Brigham and Women's Hospital)H-Index: 1
view all 10 authors...
Background The EMPA‐REG OUTCOME trial showed that empagliflozin reduced the risk of cardiovascular death and hospitalization for heart failure (HHF) in diabetic patients with cardiovascular disease. EMPRISE is a study programme on the effectiveness, safety and healthcare utilization of empagliflozin in routine care, leveraging real‐world data from two commercial and one federal US data sources from 2014 to 2019.
Source
12345678